AI in GxP is not one problem. It is a spectrum of problems that share a common regulatory context but require fundamentally different solutions depending on what the AI is doing and what decisions it influences. A literature search assistant and an automated batch-release system both use AI in a GxP environment. They have almost nothing else in common from a compliance perspective. The framework that handles this spectrum starts with risk classification and ends with continuous regulatory compliance — and every step in between must be documented, defensible, and inspection-ready.
Risk classification: the foundation everything else depends on
Every AI use case in a GxP environment must be classified by risk before any other decision is made. The classification determines: how deep the validation must go, how much human oversight is required, how intensive the monitoring must be, and what regulatory evidence must be produced. Get the classification wrong and everything downstream is either over-engineered (wasting resources) or under-engineered (creating compliance exposure).
A practical classification framework uses three dimensions:
- Impact on product quality. Does the AI output directly affect a product quality decision? Batch release, specification setting, and in-process control decisions are high-impact. Document formatting, scheduling, and literature search are low-impact.
- Impact on patient safety. Does the AI output influence a decision that could directly affect patient outcomes? Dosage calculation, adverse event detection, and safety signal assessment are high-impact. Training material generation and SOP formatting are low-impact.
- Impact on data integrity. Does the AI system create, modify, or interpret GxP-relevant data? If the AI generates content that becomes part of a regulatory record, data integrity requirements apply. If it generates internal working documents that are reviewed and rewritten by humans, the data integrity requirements are lighter.
Classification Engine in GxP Copilot automates this classification using a rule-based engine that maps AI use cases to risk tiers and GAMP 5 categories, producing a documented rationale for each classification decision.
GAMP 5 category mapping for AI systems
GAMP 5 Second Edition categorises computerised systems into five categories. AI systems map as follows:
- Category 1 (Infrastructure software). Operating systems, databases, cloud infrastructure that the AI runs on. Qualified, not validated.
- Category 3 (Non-configured commercial software). Pre-trained models used as-is without fine-tuning (e.g., a cloud API for OCR or text extraction). Verified by the vendor; you qualify the integration.
- Category 4 (Configured commercial software). A commercial AI platform configured for your use case — such as GxP Copilot deployed with your organisation's requirements. Configuration validation: IQ/OQ/PQ with risk-based test depth.
- Category 5 (Custom software). Internally developed AI models, fine-tuned models, custom integrations, or bespoke AI pipelines. Full software development lifecycle validation: requirements, design, code review, unit testing, integration testing, IQ/OQ/PQ.
The category determines the validation effort. Category 3 is lightest; Category 5 is heaviest. Most organisations that build AI solutions internally are surprised by how much Category 5 validation costs — which is why commercial Category 4 platforms like GxP Copilot exist.
Regulatory expectations by authority
FDA expects risk-based assurance proportional to the system's impact. The CSA guidance (2023) applies: critical-thinking-based testing for high-risk functions, scripted testing where reproducibility matters, and leveraged vendor evidence where appropriate. For AI/ML SaMD, the Predetermined Change Control Plan framework allows pre-approved model updates within defined bounds.
EMA / EU GMP adds Annex 22's explicit requirements for AI in GMP: governance, safeguards, HITL, fallback, and evaluation. These are not optional for EU-regulated sites. Annex 11 / 22 in GxP Copilot implements all six elements.
MHRA aligns with EU GMP expectations and adds emphasis on post-market surveillance for AI systems. MHRA expects documented evidence of ongoing AI performance monitoring, not just point-in-time validation.
Health Canada participates in the GMLP (Good Machine Learning Practice) framework with FDA and MHRA. Expectations are converging toward risk-based validation with continuous monitoring.
Building the compliance architecture
- Governance layer. AI use-case intake, risk classification, approval workflow, model registry. Owned by a cross-functional governance board.
- Validation layer. GAMP 5 lifecycle applied to each AI system: URS, risk assessment, IQ/OQ/PQ, traceability matrix, validation summary report. GxP Copilot generates the full package.
- Operational layer. HITL workflows, approval gates, segregation of duties, electronic signatures. Part 11 and Annex 11 compliant.
- Monitoring layer. Performance dashboards, drift detection, alerting, periodic re-qualification. Continuous validation evidence.
- Audit layer. Tamper-evident audit trail, hash-chained records, independent verification capability. The audit trail covers every AI output, every human review, every approval, and every system change.
The inspection scenario
An inspector examining your AI system will ask: what does it do, how was it classified, what is the validation evidence, how do you know it is still performing as validated, what happens when it fails, and can you show me the audit trail. The framework in this article — classification, GAMP 5 mapping, regulatory alignment, HITL design, continuous monitoring, and audit trail — produces the evidence that answers every one of those questions. book a demo to see how GxP Copilot implements this framework end-to-end.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.